Emmanuel Dornier
Emmanuel Dornier, Nelson Dusetti, Xavier Iturrioz

Emmanuel Dornier: Securing First Major ARC Foundation Funding to Advance PDAC Research

Emmanuel Dornier, Junior Professor at IMRB, shared a post on LinkedIn:

“What a milestone!

We just secured our first major funding from the ARC Foundation for Cancer Research,!! And will be recruiting soon.

We’ll coordinate a world-class consortium within the ultra-competitive PANCREAS 2025 program, bringing together:

  1.  Xavier Iturrioz (Servent Lab, CEA): expert in GPCR signaling and pharmacological targeting
  2.  Nelson Dusetti (Dusetti–Iovanna Lab, CRCM): world leader in pancreatic cancer translational and therapeutic research

Project DISSRUPT — Decoding Intercellular Stromal Signaling via GPCRs to Unravel new PDAC Therapies

Background: We found that GPCRs are profoundly deregulated in the most aggressive pancreatic tumors

Goal: Identify new actionable targets to disrupt the PDAC stroma

This funded project will contribute to the growing translational oncology effort at Henri Mondor Hospital, IMRB – Mondor Institute for Biomedical Research and the newly established Henri-Mondor University Cancer Institute, strengthening the bridge between research and clinical care.

We can’t thank enough the Fondation ARC and their scientific committee for this vote of confidence in our young lab: it’s an incredible opportunity to bring together leading teams in GPCR biology and pancreatic cancer research to advance patient care.”

Emmanuel Dornier: Securing First Major ARC Foundation Funding to Advance PDAC Research

Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared this post, adding:

“Glad that our team is part of DISSRUPT. Many thanks to ARC Foundation for Cancer Research for their trust and to Emmanuel Dornier for involving us in this project.

Our team is committed to improving current culture models to make preclinical research more relevant for translational studies, and by contributing patient-derived organoids and CAF co-culture systems, we aim to functionally assess how stromal GPCR signaling shapes invasion and treatment response, with the goal of identifying targets that can truly benefit PDAC patients.”

More posts featuring Nelson Dusetti.